Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy - PubMed (original) (raw)
Clinical Trial
Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy
Michael F H Schocke et al. Neuroimage. 2003 Oct.
Abstract
To evaluate biochemical changes in contrast-enhancing multiple sclerosis (MS) lesions, we examined 14 patients with relapsing-remitting MS at acute clinical exacerbation with the help of contrast-enhanced magnetic resonance imaging (MRI) and 1H magnetic resonance spectroscopic imaging (1H MRSI). Using a 1.5-tesla MR system (Magnetom Vision, Siemens, Germany), we followed 29 contrast-enhancing and 24 nonenhancing MS lesions as well as normal-appearing white matter (NAWM) before and during high-dose methylprednisolone (HDMP) therapy. Metabolite ratios of N-acetylaspartate (NAA), choline (Cho), creatine (Cr), and lactate (Lac) were calculated. A transient decrease in contrast enhancement under HDMP therapy was observed. Both groups of MS lesions showed significantly decreased NAA to Cr ratios compared to NAWM with no changes in time. Baseline 1H MRSI revealed significantly increased Cho to Cr ratios in the contrast-enhancing MS lesions (1.13 +/- 0.25) compared to the nonenhancing MS lesions (0.85 +/- 0.26, P < 0.001) and NAWM (0.97 +/- 0.22, P = 0.015). Both the contrast-enhancing and the nonenhancing MS lesions exhibited a significant increase in Cho to Cr ratios from the second to the third 1H MRSI. We identified resonances of lactate in both groups of MS lesions and NAWM without any significant group differences or changes over time. 1H MRSI provides additional information that help to estimate macrophages' activity, cell membrane activation, and neuronal impairment within MS lesions. We believe that combined contrast-enhanced MRI and 1H MRSI may help to further investigate inflammatory processes within active MS lesions and should be employed more frequently to the research on therapy effects in MS.
Similar articles
- Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging.
Husted CA, Goodin DS, Hugg JW, Maudsley AA, Tsuruda JS, de Bie SH, Fein G, Matson GB, Weiner MW. Husted CA, et al. Ann Neurol. 1994 Aug;36(2):157-65. doi: 10.1002/ana.410360207. Ann Neurol. 1994. PMID: 8053651 - [Differences in the spectroscopy of the lesions of the remitting relapsing form of multiple sclerosis shown by magnetic resonance].
Martínez-Bisbal MC, Celda B, Martí-Bonmat L, Casanova-Estruch B, Coret-Ferrer F. Martínez-Bisbal MC, et al. Rev Neurol. 2002 May 1-15;34(9):807-12. Rev Neurol. 2002. PMID: 12134339 Spanish. - Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
Then Bergh F, Kümpfel T, Schumann E, Held U, Schwan M, Blazevic M, Wismüller A, Holsboer F, Yassouridis A, Uhr M, Weber F, Daumer M, Trenkwalder C, Auer DP. Then Bergh F, et al. BMC Neurol. 2006 May 23;6:19. doi: 10.1186/1471-2377-6-19. BMC Neurol. 2006. PMID: 16719908 Free PMC article. Clinical Trial. - Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ. Fox EJ. Clin Ther. 2006 Apr;28(4):461-74. doi: 10.1016/j.clinthera.2006.04.013. Clin Ther. 2006. PMID: 16750460 Review.
Cited by
- Differential expression of glucose-metabolizing enzymes in multiple sclerosis lesions.
Nijland PG, Molenaar RJ, van der Pol SM, van der Valk P, van Noorden CJ, de Vries HE, van Horssen J. Nijland PG, et al. Acta Neuropathol Commun. 2015 Dec 4;3:79. doi: 10.1186/s40478-015-0261-8. Acta Neuropathol Commun. 2015. PMID: 26637184 Free PMC article. - Combination of Probiotics and Natural Compounds to Treat Multiple Sclerosis via Warburg Effect.
Ravi AK, Muthukrishnan SK. Ravi AK, et al. Adv Pharm Bull. 2022 May;12(3):515-523. doi: 10.34172/apb.2022.057. Epub 2021 Sep 29. Adv Pharm Bull. 2022. PMID: 35935051 Free PMC article. Review. - Innate immune cells and myelin profile in multiple sclerosis: a multi-tracer PET/MR study.
Pitombeira MS, Koole M, Campanholo KR, Souza AM, Duran FLS, Solla DJF, Mendes MF, Pereira SLA, Rimkus CM, Busatto GF, Callegaro D, Buchpiguel CA, de Paula Faria D. Pitombeira MS, et al. Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4551-4566. doi: 10.1007/s00259-022-05899-2. Epub 2022 Jul 15. Eur J Nucl Med Mol Imaging. 2022. PMID: 35838758 - Chemical shift magnetic resonance spectroscopy of cingulate grey matter in patients with minimal hepatic encephalopathy.
Mechtcheriakov S, Schocke M, Kugener A, Graziadei IW, Mattedi M, Hinterhuber H, Vogel W, Marksteiner J. Mechtcheriakov S, et al. Neuroradiology. 2005 Jan;47(1):27-34. doi: 10.1007/s00234-004-1298-8. Epub 2005 Jan 18. Neuroradiology. 2005. PMID: 15655660 - Magnetic resonance imaging for the diagnosis of Parkinson's disease.
Heim B, Krismer F, De Marzi R, Seppi K. Heim B, et al. J Neural Transm (Vienna). 2017 Aug;124(8):915-964. doi: 10.1007/s00702-017-1717-8. Epub 2017 Apr 4. J Neural Transm (Vienna). 2017. PMID: 28378231 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources